MARKET WIREYahoo • 2d ago
Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?The stock has experienced a pullback in the past few months.
Why AXSM Stock Traded Steady Today — RQD Quant Desk Flash
$143.45 -0.04% NASDAQ • Public Delayed / 60s Snapshot
Axsome Therapeutics Inc. (AXSM) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ROARABLE D+ • SELL / AVOID
Cap $7.51B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.4M)
46% PutsMax Pain: $141.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AXSM Stock Traded Steady Today — RQD Quant Desk Flash
Axsome Therapeutics Inc. (AXSM) slipped -0.04% to $143.45 as options desks priced 54% call premium vs. 46% put protection around the $141 max-pain magnet. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($123.5 – $260.19) with RSI-14 at 24.3 (OVERSOLD (<32)).
- ▸Whale Options Positioning: $2.4M in bullish call flow vs. $2.1M in put flow (Put/Call 0.86x, implied earnings swing ±7.4%).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 44% gross margin and $0 annual free cash flow.
Live AXSM Headlines & Catalysts
CATALYSTYahoo • 3d ago
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityAxsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
CATALYSTYahoo • 4d ago
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 5d ago
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowAxsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREBenzinga • 5d ago
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
CATALYSTYahoo • 8d ago
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)These drugmakers are capitalizing on their pipeline successes.
CATALYSTYahoo • 10d ago
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
MARKET WIREBenzinga • 11d ago
Top 3 Health Care Stocks That Could Blast Off In OctoberInsmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring AXSM)
- ✓Live walkthrough of AXSM's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
AXSM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.48%🛡️ HOLDING TREND SUPPORT
2026-10-30O $143.2H $146.2L $131.3C $144.4VOL 2.17M
RES: $211.2SUP: $138.1SMA50: $184.8SMA200: $199.3
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AXSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
27.0%/yr Implied 5Y Growth
vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AXSM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AXSM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AXSM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
AXSM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AXSM stock moving today?
Why AXSM Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.